Echo IQ Expands AI Healthcare Reach Through Mayo Clinic Collaboration
Echo IQ Limited (ASX: EIQ) has secured a research partnership with Mayo Clinic to assess the effectiveness of its artificial intelligence technology in identifying cardiac risks among cancer patients receiving treatment. The study will explore whether AI-driven analysis of routinely collected heart imaging data can help predict the risk of heart failure before symptoms develop. This initiative targets the rapidly growing cardio-oncology field, where healthcare providers are increasingly focused on managing cardiovascular complications linked to cancer therapies. With millions of patients worldwide undergoing cancer treatment each year, the ability to detect heart-related risks earlier could support more informed clinical decisions and improve patient outcomes. The research will utilise anonymised echocardiographic data processed through Echo IQ’s proprietary AI platform to generate predictive risk assessments. Beyond evaluating its role in oncology, the project also offers an opportunity to demonstrate the broader clinical value of Echo IQ’s technology across new patient populations. Successful outcomes could strengthen the company’s position in the expanding AI-powered healthcare market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Echo IQ Expands AI Healthcare Reach Through Mayo Clinic Collaboration
Echo IQ Limited (ASX: EIQ) has secured a research partnership with Mayo Clinic to assess the effectiveness of its artificial intelligence technology in identifying cardiac risks among cancer patients receiving treatment. The study will explore whether AI-driven analysis of routinely collected heart imaging data can help predict the risk of heart failure before symptoms develop. This initiative targets the rapidly growing cardio-oncology field, where healthcare providers are increasingly focused on managing cardiovascular complications linked to cancer therapies. With millions of patients worldwide undergoing cancer treatment each year, the ability to detect heart-related risks earlier could support more informed clinical decisions and improve patient outcomes. The research will utilise anonymised echocardiographic data processed through Echo IQ’s proprietary AI platform to generate predictive risk assessments. Beyond evaluating its role in oncology, the project also offers an opportunity to demonstrate the broader clinical value of Echo IQ’s technology across new patient populations. Successful outcomes could strengthen the company’s position in the expanding AI-powered healthcare market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au